Trials / Completed
CompletedNCT02432937
Corever in the Treatment of Hypertension
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study of Corever for the Treatment of Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- TSH Biopharm Corporation Limited · Industry
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The study primarily aims to compare the effects of two doses of Corever with placebo in patients with hypertension.
Detailed description
The study aims to compare the effects of two doses of Corever with placebo in patients with essential hypertension. Eligible subjects who belong to one of the following subtypes are planned to be enrolled: (1) patients with essential hypertension without drug control, or (2) uncontrolled hypertension despite treatment with up to 2 antihypertensive agents. Of note, the second category will receive randomized study treatments in addition to continuing their previous medication throughout the trial. The study also wants to investigate the safety profile of Corever during treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Corever | Corever |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-06-01
- Completion
- 2016-08-01
- First posted
- 2015-05-04
- Last updated
- 2016-11-04
Locations
8 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02432937. Inclusion in this directory is not an endorsement.